Abstract
Background: To study lipid profile in Beta-Thalassemia Major Patients.
 Methods: A cross-sectional was done on 30 diagnosed Cases of beta-thalassemia major in the age group of 1 year to 18 years receiving regular blood transfusions; not suffering from any ailment or any other disease leading to deranged lipid profile were included.
 Results: Lipid analyses of controls and thalassemic children. It is clear from the results that beta thalassemia major patients had significantly lower total cholesterol (TC), high-density lipoprotein cholesterol (HDL) and low-density lipoprsotein cholesterol (LDL) compared with controls.
 Conclusion: Lipid profile in Beta thalassmia patients show significantly low levels of total cholesterol, LDLC and HDL-C.
 Keywords: Beta Thalassemia Major, Lipid Profile, LDL, HDL.
Highlights
Beta-thalassemia is the commonest single-gene disorder in the Indian population
A cross-sectional was done on 30 diagnosed Cases of beta-thalassemia major in the age group of 1 year to 18 years receiving regular blood transfusions; not suffering from any ailment or any other disease leading to deranged lipid profile were included
It is clear from the results that beta thalassemia major patients had significantly lower total cholesterol (TC), high-density lipoprotein cholesterol (HDL) and low-density lipoprsotein cholesterol (LDL) compared with controls
Summary
Beta-thalassemia is the commonest single-gene disorder in the Indian population. Beta thalassemia major is caused by complete absence of beta globin chain production resulting from reduced synthesis of one or more globin chains which can be caused by different globin gene mutation resulting in ineffective hematopoiesis, increased hemolysis and early onset anemia. There are about 240 million carriers of β-thalassemia worldwide, i.e. 1.5% of world population. A WHO update on betathalassemia in India indicated a similar overall carrier frequency of 3–4%, based on that the current national population would translate to between 35.6 and 47.5 million carriers of the disorder nationwide. The mainstay of treatment of thalassemia is regular blood (Packed Red Blood Cells) transfusions. The major complications of blood transfusion are those related to transmission of infectious agents or development of iron overload.[3,4]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Medical and Biomedical Studies
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
